• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Health Products Association - China Executive Director Reflects on Market Dynamics, Challenges

    Blood Sugar Management: Personalized Testing Drives Home The Need for Early Intervention

    New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance

    Tapping Functional Beverages to Meet Modern Wellness Needs

    Adaptogens: Where Ancient Remedies Meet Modern Wellness Products
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Pharmavite Expands in Ohio with $200 Million Investment

    Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company

    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products

    NOW Identifies Misleading Certificate of Analysis for Supplements Sold on Amazon

    Kensing Acquires Vitae Naturals
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Kensing Acquires Vitae Naturals

    Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast

    CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise

    Shiitake Mushroom Extract Appears Helpful in HPV Infections

    United Plant Savers Launches First Film Festival
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Pharmavite Expands in Ohio with $200 Million Investment

    Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company

    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products

    NOW Identifies Misleading Certificate of Analysis for Supplements Sold on Amazon

    Kensing Acquires Vitae Naturals
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products

    Lynside® Forte B offers full range of B-vitamin benefits with nutritional yeast

    CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise

    Shiitake Mushroom Extract Appears Helpful in HPV Infections

    Upcycled Coffeeberry® Cascara Offers Versatility in Functional Beverage Development
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    PhytoGaia Inc

    Verdure Sciences

    Nutrition21, LLC

    Sabinsa Corporation

    Xsto Solutions
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    PhytoGaia Inc

    Verdure Sciences

    Nutrition21, LLC

    Sabinsa Corporation

    Xsto Solutions
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Epanova Phase III Trial Begins

    Omthera’s keystone EPA/DHA ingredient to be studied in conjunction with statin therapy in hypertriglyceridemic patients.

    Related CONTENT
    • STRENGTH Trial Finds Omega-3s Didn’t Reduce Cardiovascular Event Risk
    • Transforming Health with Nature’s Sunshine
    • Understanding FTC Standards for Claims Substantiation
    • Omega-3s Show Benefit for Memory & Cognition
    • TREHA Trehalose Available As ‘Natural Flavor’
    Joanna Cosgrove09.15.11
    Omthera Pharmaceuticals, Inc., a Bedminster, NJ-based privately-held, emerging specialty pharmaceuticals company, has begun enrollment for its Phase III clinical trial to determine the effects of its EPA/DHA compound called Epanova on patients with persistent hypertriglyceridemia despite statin therapy. 

    Epanova is Omthera’s ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and is currently in development as a “prescription omega 3 free fatty acid for the treatment of patients with very high triglycerides” (greater than or equal to 500 mg/dL).  
     
    Hypertriglyceridemia is one component of a range of lipid disorders collectively referred to as dyslipidemia. The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million, with more than 27 million of those diagnosed with hypertriglyceridemia (TGs greater than 200 mg/dL) and an estimated five million with very high triglyceride levels (TGs greater than 500 mg/dL). Very high triglycerides are associated with an increased risk of pancreatitis. Regulatory approval for the treatment of very high triglycerides is based on a significant reduction in serum triglyceride levels.
     
    The randomized, double-blind, placebo-controlled, parallel group trial—called ESPRIT (short for Epanova combined with a Statin in Patients with HypertRiglycerIdemia to Reduce Non-HDL CholesTerol)—will span 6 weeks, and is designed to confirm if adding Epanova (2 grams or 4 grams daily) to existing statin monotherapy can beneficially impact the non-HDL cholesterol levels of those who are at high risk for cardiovascular disease. The secondary objectives of the trial are to evaluate the safety of the Epanova and statin combination therapies, and to evaluate the effects of the combination therapies on other lipids and lipoproteins.
     
    The first of an expected 642 total subjects has already been enrolled for the trial, which will be conducted at approximately 100 sites across the U.S.
     
    The trial was granted a Special Protocol Assessment (SPA) from FDA—an agreement between the company and the FDA indicating that the company’s proposed trial protocol design, clinical endpoints and statistical analyses are acceptable to support regulatory approval. Final marketing approval will depend upon efficacy results, adverse event profiles and an evaluation of the benefit/risk of a treatment as demonstrated in the trial.  
     
    Dr. Stephen Nicholls, assistant professor of Molecular Medicine and the cardiovascular director of the Cleveland Clinic Coordinating Center for Clinical Research and principal investigator for the ESPRIT study pointed out how the outcome of the clinical trial could beneficially impact millions of Americans currently on statin therapy who remain at risk for cardiovascular events. “Non-HDL-C is an important target of drug therapy for patients on a statin with TG between 200 and 500 mg/dL,” he said. “The results of this trial, if positive, could further support the use of omega 3 free fatty acids as a treatment for these patients.”
     
    Dr. Michael Davidson, chief medical officer and co-founder of Omthera, echoed Dr. Nicholls’ optimism. “Data generated earlier this year demonstrated that Epanova has superior bioavailability compared to the market leader, Lovaza, and our EVOLVE trial, intended to support our planned NDA filing, has been actively enrolling subjects,” he said. “With the initiation of the ESPRIT trial, we have now taken a further step to potentially expand the indication to include patients with persistent hypertriglyceridemia and high risk for cardiovascular disease, who are on statin therapy, for which there are currently no approved prescription omega 3 drugs.”
     
    The company pointed to a growing body of data supporting Epanova and noted its improved and more predictable bioavailability as compared to the ethyl ester form found in prescription omega 3 products currently available. “Triglyceride lowering with Epanova was previously observed in two large placebo-controlled, randomized, double-blind Phase III studies involving 748 Crohn's Disease patients with normal triglyceride levels for greater than or equal to 52 weeks; approximately 400 of which were treated with Epanova for remission of disease. In all studies performed to date, Epanova has demonstrated a very good safety and tolerability profile,” the company stated via press release.
     
    In addition to the ESPRIT trial, Omthera is also involved in the ongoing Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial, which received SPA approval in November 2010, and will form the basis for filing a New Drug Application (“NDA”) with FDA. The company said the results of the ESPRIT trial are not required for regulatory approval, but rather, if positive, would serve to expand the use of Epanova to a larger patient population.
    Related Searches
    • Fatty Acids
    • Lipids
    • Omega 3
    • Research
    Related Knowledge Center
    • Cardiovascular Health
    • Fatty Acids
    • Regulations
    Suggested For You
    STRENGTH Trial Finds Omega-3s Didn’t Reduce Cardiovascular Event Risk STRENGTH Trial Finds Omega-3s Didn’t Reduce Cardiovascular Event Risk
    Understanding FTC Standards for Claims Substantiation Understanding FTC Standards for Claims Substantiation
    Transforming Health with Nature’s Sunshine Transforming Health with Nature’s Sunshine
    Omega-3s Show Benefit for Memory & Cognition Omega-3s Show Benefit for Memory & Cognition
    TREHA Trehalose Available As ‘Natural Flavor’ TREHA Trehalose Available As ‘Natural Flavor’
    AHPA Encourages EPA to Reform Pesticide Regulations AHPA Encourages EPA to Reform Pesticide Regulations
    ConsumerLab.com Tests Popular Vitamin D Supplements ConsumerLab.com Tests Popular Vitamin D Supplements
    Gottlieb Confirmed to Lead FDA Gottlieb Confirmed to Lead FDA
    GOED Study Shows New Zealand Fish Oil Supplements Meet Label Claims GOED Study Shows New Zealand Fish Oil Supplements Meet Label Claims
    Organic & Natural Health Association Hosts Consumer Education Program Organic & Natural Health Association Hosts Consumer Education Program
    Pantesin Pantethine Lowers Bad Cholesterol by 11% Pantesin Pantethine Lowers Bad Cholesterol by 11%
    Shut Up & Take Your Meds Shut Up & Take Your Meds
    Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    Review Supports Diverse Benefits of CoQ10, Examines Absorption Variability Review Supports Diverse Benefits of CoQ10, Examines Absorption Variability
    AMR101 Takes on Lovaza
AMR101 Takes on Lovaza

    Related Breaking News

    • Breaking News | Cardiovascular Health | Dietary Supplements | Medical Nutrition | Omega-3s | Research | Research News | World Markets
      STRENGTH Trial Finds Omega-3s Didn’t Reduce Cardiovascular Event Risk

      STRENGTH Trial Finds Omega-3s Didn’t Reduce Cardiovascular Event Risk

      No significant differences were observed between omega-3s and corn oil in major adverse cardiovascular outcomes in a study published in JAMA.
      11.16.20

    • Dietary Supplements | Digestive Health | Healthcare Trends | Herbs & Botanicals | Quality & Safety | World Markets
      Transforming Health with Nature’s Sunshine

      Transforming Health with Nature’s Sunshine

      With a long history in the supplement market, Nature’s Sunshine remains committed to quality and innovation.
      By Sean Moloughney, Editor 06.02.17

    • Dietary Supplements | Regulations | Research
      Understanding FTC Standards for Claims Substantiation

      Understanding FTC Standards for Claims Substantiation

      Randomized clinical trials aren’t the only source of competent and reliable scientific evidence.
      By Todd Harrison, Venable 06.02.17


    • Breaking News | Cognitive Function | Omega-3s | Research | Research News

      Omega-3s Show Benefit for Memory & Cognition

      Correlation found between omega-3 levels and increased blood flow in brain regions associated with memory/learning.
      05.25.17

    • Breaking News | Flavors & Colors | Supplier News

      TREHA Trehalose Available As ‘Natural Flavor’

      With improved manufacturing process, TREHA trehalose is now produced from non-GM starch using non-GM enzymes.
      05.25.17

    Loading, Please Wait..
    Trending
    • Three Grams Of Omega-3s May Be Optimal Dose For Reducing Blood Pressure
    • 3 grams of Omega-3s May be Optimal Dose for Reducing Blood Pressu
    • High Blood DHA Levels Linked To 49% Reduced Risk Of Alzheimer’s
    • CoQ10 And Royal Jelly Supplementation May Improve High Intensity Exercise
    • First Day Life Shuts Down Children's Behavioral, Cognitive Health Claims Following Challenge
    Breaking News
    • Pharmavite Expands in Ohio with $200 Million Investment
    • Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
    • Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
    • NOW Identifies Misleading Certificate of Analysis for Supplements Sold on Amazon
    • Kensing Acquires Vitae Naturals
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • Tapping Functional Beverages to Meet Modern Wellness Needs
    • Adaptogens: Where Ancient Remedies Meet Modern Wellness Products
    • New and Evolving Formulation Options Must Be Mindful of Blood Sugar Maintenance
    • Health Products Association - China Executive Director Reflects on Market Dynamics, Challenges
    • Blood Sugar Management: Personalized Testing Drives Home The Need for Early Intervention
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Pharmavite Expands in Ohio with $200 Million Investment
    Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
    Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
    Coatings World

    Latest Breaking News From Coatings World

    Azelis Acquires Chemical Partners, Strengthens Leadership in Africa and Middle East
    Emmanuelle Bromet Named Arkema Sustainable Development VP
    ROSS Planetary Dual Dispersers Have Unique Processing Flexibility
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—July 2
    OmniGuide Awarded FDA Clearance for RevoLix Hybrid Thulium Laser
    Pancryos Forges License Agreement for Microencapsulation Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bayer Opens New Research and Innovation Center at Kendall Square
    Lonza Names Maria Soler Nunez as Head, Group Operations
    Eurofins DiscoverX Opens Shanghai Office
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Dexlevo Introduces Beauty Treatment technique, ‘GOURI’
    Revision Skincare Exec Wins Ernst & Young Entrepreneur of the Year
    Latest Updates About Cosmoprof North America
    Happi

    Latest Breaking News From Happi

    SCOTUS EPA Ruling Won’t Impact General Regulatory Authority
    Toning Collection For Zero-Brass Blondes is New at Colorproof
    Esthetician Studio Beauty Concepts Files Trademark Infringement Lawsuit Against Kim Kardashian and Coty, Inc.
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Flint OPS, Xerox and MNYPIA Top This Week’s News
    Azelis Acquires Chemical Partners, Adds to Leadership in Africa and Middle East
    International Paper Publishes 2021 Sustainability Report
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    UPM Raflatac boosts operations in US, All4Labels returns to HP and more
    Fedrigoni Self-Adhesives to exhibit at Labelexpo Americas for first time
    CELAB Europe wins Paper Recycling award
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Glatfelter, Blue Ocean Closures Partner with Absolut
    What You’re Reading on Nonwovens-Industry.com
    Daio, Livedo Partner to Recycle Diapers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—July 2
    NuVasive Inc. Opens Singapore Experience Center
    Pedicle Screw Systems Market to Top $3B in 2027
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: eMagin, Identiv, and Japan Display Top This Week’s Stories
    Epishine is Building a New Solar Cell Factory in Linköping, Sweden
    Toppan Establishes CVC Fund and Investment Management Company in the US

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login